載入...
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies
Obatoclax mesylate is an intravenously-administered drug under investigation in Phase I and II clinical trials as a novel anticancer therapeutic for hematological malignancies and solid tumors. Obatoclax was developed as a pan-inhibitor of antiapoptotic members of the B cell chronic lymphocytic leuk...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3601645/ https://ncbi.nlm.nih.gov/pubmed/23515850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S42568 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|